We serve Chemical Name:STACHYOSE CAS:470-55-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:STACHYOSE
CAS.NO:470-55-3
Synonyms:LUPEOSE;TRANS-4-TERT-BUTYLCYCLOHEXYL ACETIC ACID;stachyose hydrate from stachys tuberifera;Gal2-Glc-Fru;Cicerose;galactosyl-(1->6)-raffinose;Gal-Gal-Glu-Fru;MANNOTETRAOSE
Molecular Formula:C24H42O21
Molecular Weight:666.57800
HS Code:2932999099
Physical and Chemical Properties:
Melting point:170ºC
Boiling point:1044.2ºC at 760mmHg
Density:1.84g/cm3
Index of Refraction:1.689
PSA:347.83000
Exact Mass:666.22200
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like LUPEOSE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MANNOTETRAOSE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Gal-Gal-Glu-Fru Use and application,6)-raffinose technical grade,usp/ep/jp grade.
Related News: “The Agency also noted that no effect was seen in the two studies that included patients from EU populations, including the most recent study which involved patients who were receiving the maximum and optimal treatment for their Parkinson’s disease,” EMA said. 1-{3-[1-(4-Chloro-benzyl)-cycloheptyloxy]-propyl}-azocane manufacturers The European Commission (EC) has approved MSD and Bayer’s Verquvo for the treatment of symptomatic chronic heart failure in patients with reduced ejection fraction. 2,5-Pyrrolidinedione, 3-(2,5-dihydro-5-thioxo-1H-tetrazol-1-yl)-1-methyl- suppliers It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. 1-(4-chlorophenyloxycarbonyl)-2-ethynyl-1,2-dihydro-4-hydroxymethylquinoline vendor & factory In response, the strategy sets out how government will work with institutions, businesses, funders and charities to drive change in the sector, with new initiatives to encourage more young people into research, broaden career pathways in the sector and look further into the impacts of bureaucracy on researchers.,“The Agency also noted that no effect was seen in the two studies that included patients from EU populations, including the most recent study which involved patients who were receiving the maximum and optimal treatment for their Parkinson’s disease,” EMA said.
